No events at this time.
PROTEINS BY DESIGN
Antibody and protein biotherapeutics are changing the way physicians treat cancer, inflammation, and autoimmune disease. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life.
Our XmAb® engineering technologies have resulted in a robust pipeline of antibody drug candidates, including seven in human clinical trials being developed by Xencor and by pharmaceutical partners.
Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.